Bulletin from the Extraordinary General Meeting in Oncopeptides AB (PUBL)

Stockholm, Sweden –December 5, 2018 – An Extraordinary General Meeting in Oncopeptides AB (publ) (ONCO) was held today, at Tändstickspalatset in Stockholm. At the Extraordinary General Meeting, the following principal resolutions were passed.

  •  The proposed remunerations to the new member of the Board of Directors were approved.
  •  Jennifer Jackson was elected as new board member until the end of the annual general meeting 2019. It is noted that the Board of Directors also consists of Per Wold-Olsen (chairman), Brian Stuglik, Jonas Brambeck, Cecilia Daun Wennborg, Jarl Ulf Jungnelius, Per Samuelsson and Olof Tydén, for the period until the end of the annual general meeting 2019.
  •  It was resolved, in accordance with the Nomination Committee’s proposal, to introduce a long-term performance-based incentive program to the additional member of the Board of Directors (“Board LTIP 2018.2”). The program is share based and intended for the new main owner independent member of the Board of Directors. The program comprises a total of not more than 2,750 share awards and the number of share awards that shall be awarded to the participant shall correspond to SEK 270,000 divided by the volume weighted average price of the Company’s share on Nasdaq Stockholm for the 10 trading days preceding the grant date. Allotment shall take place before the annual general meeting 2019 at the latest. The share awards are subject to performance vesting based on the development of the price of the Company’s share over the period from the grant date up until the final vesting date, which occurs three years after the grant date. Each vested share award entitles the holder to receive one share in the Company without any compensation being payable provided that the holder is still a Board member of the Company at the relevant times of vesting. It was further resolved, in accordance with the Nomination Committee’s proposal, to issue not more than 2,750 warrants in order to ensure delivery of shares under Board LTIP 2018.2.

For further information, please contact:
Jakob Lindberg, CEO at Oncopeptides
Telephone: +46 8 615 20 40
E-mail: jakob.lindberg@oncopeptides.com

Rein Piir, Head of Investor Relations at Oncopeptides
Telephone: +46 70 853 72 92
E-mail: rein.piir@oncopeptides.com

About Oncopeptides

Oncopeptides is a pharmaceutical company developing drugs for the treatment of cancer. The company is focusing on the development of the lead product candidate melflufen (Ygalo®), a peptide conjugated alkylator, belonging to a new class of drugs called Peptidase Enhanced Compounds. Melflufen is intended as an effective treatment of hematological cancers, and in particular multiple myeloma. The goal with the current clinical study program is to demonstrate better results from treatment with melflufen compared with established alternative drugs for patients with late-stage multiple myeloma. Melflufen will potentially provide physicians with a new treatment option for patients suffering from this serious disease.

The above information was released for public disclosure on December 5, 2018 at 16:15 p.m. (CET).